Cargando…
Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study
PURPOSE: To evaluate long-term, real-world treatment patterns and outcomes of ranibizumab 0.5 mg for neovascular age-related macular degeneration (nAMD) in a Belgian cohort. PATIENTS AND METHODS: This Belgian (BE) cohort of the 5-year global observational LUMINOUS study included 229 patients with nA...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277576/ https://www.ncbi.nlm.nih.gov/pubmed/32581505 http://dx.doi.org/10.2147/OPTH.S242547 |
_version_ | 1783543150289092608 |
---|---|
author | Leys, Anita M Ramboer, Eva Favreau, Mérédis Denhaerynck, Kris MacDonald, Karen Abraham, Ivo Brié, Heidi |
author_facet | Leys, Anita M Ramboer, Eva Favreau, Mérédis Denhaerynck, Kris MacDonald, Karen Abraham, Ivo Brié, Heidi |
author_sort | Leys, Anita M |
collection | PubMed |
description | PURPOSE: To evaluate long-term, real-world treatment patterns and outcomes of ranibizumab 0.5 mg for neovascular age-related macular degeneration (nAMD) in a Belgian cohort. PATIENTS AND METHODS: This Belgian (BE) cohort of the 5-year global observational LUMINOUS study included 229 patients with nAMD. Outcomes included visual acuity (VA), central retinal thickness (CRT) and safety. RESULTS: The mean age was 79.5±7.7 years. The majority of patients (67.7%) were female and all patients were Caucasian. Most patients previously received ranibizumab with only 17.5% of patients being treatment-naïve. The injection frequency declined over time irrespective of prior treatment status (p<0.0001), with treatment-naïve eyes receiving a mean of 4.2±2.9 yearly injections and prior-ranibizumab eyes 3.6±2.7. Regression analysis confirmed first-year VA increases for treatment-naïve eyes (p=0.002) followed by a slight decrease of −1.8 letters per year. For prior-ranibizumab eyes, the visual changes over 1 year were statistically non-significant (p=0.90) but declined slightly after year one (p<0.0001). Anatomically, the CRT of treatment-naïve eyes decreased over time from baseline (p<0.0001), whereas the CRT of prior-ranibizumab eyes remained stable (p=0.43). No new safety findings were identified. CONCLUSION: LUMINOUS-BE reconfirms the well-characterized benefit-risk profile of ranibizumab for nAMD treatment. The observed low injection frequency reflects a need for more rigorous treatment in real-world settings. CLINICAL TRIAL REGISTRATION: NCT01318941. |
format | Online Article Text |
id | pubmed-7277576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-72775762020-06-23 Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study Leys, Anita M Ramboer, Eva Favreau, Mérédis Denhaerynck, Kris MacDonald, Karen Abraham, Ivo Brié, Heidi Clin Ophthalmol Original Research PURPOSE: To evaluate long-term, real-world treatment patterns and outcomes of ranibizumab 0.5 mg for neovascular age-related macular degeneration (nAMD) in a Belgian cohort. PATIENTS AND METHODS: This Belgian (BE) cohort of the 5-year global observational LUMINOUS study included 229 patients with nAMD. Outcomes included visual acuity (VA), central retinal thickness (CRT) and safety. RESULTS: The mean age was 79.5±7.7 years. The majority of patients (67.7%) were female and all patients were Caucasian. Most patients previously received ranibizumab with only 17.5% of patients being treatment-naïve. The injection frequency declined over time irrespective of prior treatment status (p<0.0001), with treatment-naïve eyes receiving a mean of 4.2±2.9 yearly injections and prior-ranibizumab eyes 3.6±2.7. Regression analysis confirmed first-year VA increases for treatment-naïve eyes (p=0.002) followed by a slight decrease of −1.8 letters per year. For prior-ranibizumab eyes, the visual changes over 1 year were statistically non-significant (p=0.90) but declined slightly after year one (p<0.0001). Anatomically, the CRT of treatment-naïve eyes decreased over time from baseline (p<0.0001), whereas the CRT of prior-ranibizumab eyes remained stable (p=0.43). No new safety findings were identified. CONCLUSION: LUMINOUS-BE reconfirms the well-characterized benefit-risk profile of ranibizumab for nAMD treatment. The observed low injection frequency reflects a need for more rigorous treatment in real-world settings. CLINICAL TRIAL REGISTRATION: NCT01318941. Dove 2020-06-02 /pmc/articles/PMC7277576/ /pubmed/32581505 http://dx.doi.org/10.2147/OPTH.S242547 Text en © 2020 Leys et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Leys, Anita M Ramboer, Eva Favreau, Mérédis Denhaerynck, Kris MacDonald, Karen Abraham, Ivo Brié, Heidi Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study |
title | Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study |
title_full | Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study |
title_fullStr | Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study |
title_full_unstemmed | Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study |
title_short | Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study |
title_sort | long-term ranibizumab treatment in neovascular age-related macular degeneration: a belgian subanalysis from the global real-world luminous(tm) study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277576/ https://www.ncbi.nlm.nih.gov/pubmed/32581505 http://dx.doi.org/10.2147/OPTH.S242547 |
work_keys_str_mv | AT leysanitam longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy AT ramboereva longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy AT favreaumeredis longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy AT denhaerynckkris longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy AT macdonaldkaren longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy AT abrahamivo longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy AT brieheidi longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy |